Sample Solution

Amenorrhea in our study was defined as absence of bleeding for 3 consecutive cycles.
Symptomatically improved patients = patients in whom cycles were 45-60 days but there was significant reduction in bleeding, reduction in PBAC score, reduction in endometrial thickness and increase in hemoglobin percentage.
In this study, the patients who are treated with oral ormeloxifene shows there was significant reduction in menstrual blood loss as assessed by fall in PBAC score (Table2). The mean pretreatment menstrual blood loss (PBAC score) was 174.20±56.93 which reduced to 22.87±29.90 at 3 months and 3.74±10.99 at 6 months with treatment. There was significant reduction in menstrual blood loss in patients with ormeloxifene. The results of this study (table-2) suggests that the rise in haemoglobin level at the end of 6 months of treatment was 11.03±1.02 compared to the pretreatment level of 10.22±1.36. The rise in haemoglobin level at the end of 6 months was significant. The mean endometrial thickness (Table-2) in the pretreatment group was 9.32±3.10 and there was decrease in mean endometrial thickness at the end of 6 months 5.84±0.99 of treatment with oral ormeloxifene.
Dhananjaya et al[6] studied 35 patients with dysfunctional uterine bleeding and found a statistically significant increase in haemoglobin concentration (8.26 to 10.59g/dl, P<0.001) and statistically significant decrease in endometrial thickness (9.83 to 4.89, P< 0.001) after 6 months of treatment with ormeloxifene.
Neha et al[5] studied 50 patients and found a PBAC score ranging from 123 – 643 pretreatment and 0-75 at the end of 6 month, decrease in endometrial thickness (11.35 to 8.13), rise in haemoglobin level (9.04 to 10.86) after 6 months of treatment with ormeloxifene.